Elicio Therapeutics, Inc. - 10-Q Filing

Elicio Therapeutics reports Q3 2026 financial results featuring significant warrant liability adjustments and ongoing equity offerings.

SEC EDGAR ·

Tickers: $ELTX

Read the full article at SEC EDGAR

More Regulatory news